Revenue Breakdown
Composition ()
No data
Revenue Streams
Prenetics Global Ltd (PRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics , accounting for 91.3% of total sales, equivalent to $59.06M. Another important revenue stream is Prevention . Understanding this composition is critical for investors evaluating how PRE navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Prenetics Global Ltd maintains a gross margin of 59.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -33.27%, while the net margin is -77.72%. These profitability ratios, combined with a Return on Equity (ROE) of -30.55%, provide a clear picture of how effectively PRE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PRE competes directly with industry leaders such as ADAC and BACC. With a market capitalization of $266.56M, it holds a significant position in the sector. When comparing efficiency, PRE's gross margin of 59.47% stands against ADAC's N/A and BACC's N/A. Such benchmarking helps identify whether Prenetics Global Ltd is trading at a premium or discount relative to its financial performance.
